85691-71-0

Usage

Uses

Used in Pharmaceutical Industry:
Imidazo[1,5-a]pyridine-5-carboxaldehyde (9CI) is used as a building block for the synthesis of various pharmaceuticals due to its diverse biological activities and potential therapeutic applications.
Used in Drug Development:
Imidazo[1,5-a]pyridine-5-carboxaldehyde (9CI) is utilized as a starting material for the development of new drugs targeting cancer, inflammation, and microbial infections, given its demonstrated anti-cancer, anti-inflammatory, and antimicrobial properties.
Used in Medicinal Chemistry Research:
Imidazo[1,5-a]pyridine-5-carboxaldehyde (9CI) serves as a subject of study in medicinal chemistry research, where its unique structure and functional groups are explored for the discovery of novel therapeutic agents and understanding of its mechanism of action.

InChI:InChI=1/C8H6N2O/c11-5-8-3-1-2-7-4-9-6-10(7)8/h1-6H

Upstream product

• 944150-30-5 ethyl 6-((1,3-dioxoisoindolin-2-yl)methyl)picolinate 
• 49668-99-7 ethyl 6-chloromethylpyridine-2-carboxylate 
• 41337-81-9 ethyl 6-(hydroxymethyl)pyridine-2-carboxylate 
• 15658-60-3 diethyl-2,6-pyridinedicarbonyl ester 
• 76292-67-6 ethyl imidazo [1,5-a]pyridine-5-carboxylate 
• 104086-21-7 6-(aminomethyl)pyridine-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES

Disclosed herein are 5 or 8-substituted imidazo[l,5-a]pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo[l,5-a]pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8- substituted imidazo[l,5-a]pyridines that can be useful for inhibiting indoleamine 2,3- dioxygenase and/or tryptophane 2,3-dioxygenase and for treating diseases or disorders mediated thereby.

Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors

Disclosed are compounds of the formula I STR1 or a 5,6,7,8-tetrahydro derivative thereof, wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, or aryl-lower alkoxy in which aryl represents phenyl or phenyl substituted by lower alkoxy, lower alkyl, halogen or trifluoromethyl; R2 represents hydrogen, halogen, or lower alkyl; C represents carboxy, lower alkoxycarbonyl, unsubstituted or mono- or di-(lower alkyl) substituted carbamoyl, cyano, formyl, hydroxymethyl, 5-tetrazolyl, dihydro-2-oxazolyl, dihydro-2-oxazolyl substituted by lower alkyl, or hydroxycarbamoyl; and (a) A represents ethenylene or ethenylene substituted by lower alkyl; B is straight chain or branched alkylene of 1 to 12 carbon atoms, alkynylene or alkenylene of 2 to 12 carbon atoms, phenylene-lower alkylene, phenylene-lower alkenylene, phenylene, or phenylene-(thio or oxy)-lower alkylene; or (b) A represents a direct bond; B represents lower alkylenephenylene, phenylene lower alkylene, phenylene, lower alkylene-(thio or oxy)-lower alkylene, lower alkylene-(thio or oxy)-phenylene, phenylene-(thio or oxy)-lower alkylene, phenylene-lower alkenylene, lower alkylenephenylene-lower alkenylene, or straight chain or branched alkadienylene of 5 to 12 carbon atoms; or a pharmaceutically acceptable salt thereof; and methods of synthesis thereof. Said compounds are useful as selective thromboxane synthetase inhibitors for the treatment of diseases such as cerebral ischaemia, shock, thrombosis and ischaemic heart disease.